STAT

Opinion: Face transplantation edges toward mainstream medicine. Insurance should cover it

Almost $1 million is a lot to pay for a face transplant. Insurers should help.
A CT of a face transplant patient.

Face transplantation, once a headline-inspiring medical treatment, is slowly moving toward mainstream medicine. Since the first such transplant in 2005, more than 40 of these procedures have been performed in more than 15 centers in nine countries. To acknowledge and support this shift, it’s time for insurers to step up and cover the cost.

For years, the standard treatment for devastating facial injuries and congenital defects was reconstructive surgery using tissue from other parts of the body. Surgeons aim to maximize the patient’s ability to breathe, eat, and see, while also restoring the natural, aesthetic appeal of the face. and may limit the individual’s ability to reintegrate into society.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About AstraZeneca CEO Pay, Alternatives To WuXi And More
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans.…
STAT2 min read
STAT+: Pharmalittle: We’re Reading About FTC Fighting ‘Junk’ Patents, Pfizer Direct-to-consumer Plans, And More
The FTC expanded its campaign against pharmaceutical companies for filing what it calls “junk” patent listings for 20 different brand-name treatments.

Related Books & Audiobooks